PERF-B19 • Group B — Pharmacological & Prohibited Performance-Enhancing Substances 🚫 WADA PROHIBITED / CONTROLLED SUBSTANCE

Peptide Hormones & Prohibited Peptide-Related Agents (GHRPs, Ipamorelin, CJC-1295, BPC-157 & GnRH Analogues)

🚫 PROHIBITED / CONTROLLED PHARMACOLOGICAL AGENT — ANTI-DOPING & CLINICAL SAFETY WARNING:
Peptide Hormones & Prohibited Peptide-Related Agents (GHRPs, Ipamorelin, CJC-1295, BPC-157 & GnRH Analogues) is classified under Group B (Pharmacological & Prohibited Performance-Enhancing Substances). It is NOT recommended as an athletic performance aid. This monograph provides objective clinical pharmacology, toxicology, Indian statutory regulation, and WADA anti-doping education only—it never provides doping cycles, stacking regimens, or testing-evasion instructions. Any legitimate therapeutic use requires specialist medical diagnosis and supervision.

1. Substance & Common Names BPC-157 (Body Protection Compound-157); TB-500 (Thymosin Beta-4 fragment); Ipamorelin; GHRP-2 (Pralmorelin); GHRP-6; Hexarelin; CJC-1295; Sermorelin; Tesamorelin; Ibutamoren (MK-677); Leuprorelin; Triptorelin

2. Pharmacological Class Growth Hormone Secretagogues (Ghrelin/GHS-R1a Agonists), GHRH Analogues, GnRH Agonists & Unapproved Experimental Peptides

3. WADA Prohibited-List Status PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S2.2 (Peptide Hormones and Releasing Factors — explicitly listing BPC-157, GnRH analogues, GHRH analogues [CJC-1295, sermorelin, tesamorelin], and GH secretagogues [ghrelin, ibutamoren MK-677, ipamorelin, GHRP-1 to -6, hexarelin]), S2.3 (TB-500 / Thymosin-beta4), and S0 (Non-Approved Substances).

4. Last Verification Date 11 November 2026 (Verified against WADA, CDSCO/FSSAI & IOC/ISSN)

1. Generic or Accepted Substance Name & Classifications

Accepted Name: Peptide Hormones & Prohibited Peptide-Related Agents (GHRPs, Ipamorelin, CJC-1295, BPC-157 & GnRH Analogues)
Common Names, Synonyms & Classifications: BPC-157 (Body Protection Compound-157); TB-500 (Thymosin Beta-4 fragment); Ipamorelin; GHRP-2 (Pralmorelin); GHRP-6; Hexarelin; CJC-1295; Sermorelin; Tesamorelin; Ibutamoren (MK-677); Leuprorelin; Triptorelin
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B19)

2. Pharmacological Class

Growth Hormone Secretagogues (Ghrelin/GHS-R1a Agonists), GHRH Analogues, GnRH Agonists & Unapproved Experimental Peptides

3. Mechanism of Action

Comprises three distinct prohibited pharmacological sub-groups under WADA S2 (and S0): (1) Growth Hormone Releasing Peptides (GHRPs: Ipamorelin, GHRP-2, GHRP-6, Hexarelin) and non-peptide mimetic Ibutamoren (MK-677) act as agonists at the pituitary/hypothalamic Ghrelin / Growth Hormone Secretagogue Receptor (GHS-R1a); (2) GHRH Analogues (CJC-1295, Sermorelin, Tesamorelin) bind pituitary GHRH receptors; and (3) Experimental regeneration peptides (BPC-157, a 15-amino-acid synthetic gastric pentadecapeptide, and TB-500, an actin-sequestering Thymosin Beta-4 fragment) are unapproved angiogenesis/growth-factor modulators.

4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)

Pharmacological Effect: GHS-R1a/GHRH agonists stimulate pulsatile pituitary GH release; BPC-157/TB-500 are investigated preclinically in rodent tendon/ligament injury models. CRITICAL SCIENTIFIC & REGULATORY REALITY: BPC-157, TB-500, CJC-1295, and Ipamorelin have ZERO regulatory approval for human therapeutic use anywhere in the world! There are no robust, peer-reviewed randomised human clinical trials proving safety or efficacy of BPC-157 or TB-500 for athletic musculoskeletal injury recovery.

5. Quality of Scientific Evidence

Evidence Assessment: UNAPPROVED EXPERIMENTAL PEPTIDES & WADA-PROHIBITED AGENTS (WADA S2.2 / S2.3 / S0) — No Approved Human Musculoskeletal Indications

6. Approved Medical Uses (Where Applicable)

Leuprorelin, Goserelin, and Triptorelin (GnRH analogues) are approved specialist oncology/endocrinology medicines for prostate cancer, endometriosis, and central precocious puberty; Tesamorelin is approved only for HIV-associated lipodystrophy. BPC-157, TB-500, CJC-1295, GHRP-6, and Ibutamoren (MK-677) have ZERO approved human medical uses.

7. Sports-Related Uses, Misuse Patterns & Contamination Risks

Heavily promoted on social media and unregulated wellness clinics as injectable or nasal 'recovery peptides' (BPC-157, TB-500) or 'GH secretagogues' (MK-677, CJC-1295, Ipamorelin). Unregulated lyophilisates purchased online carry severe risks of bacterial endotoxin (pyrogen) contamination, trifluoroacetic acid (TFA) synthesis residues, misfolded peptide aggregates, and anaphylaxis.

🔬 Supplement Contamination & Undeclared-Ingredient Risk Notice: International analytical studies (IOC Consensus Statement) demonstrate that 10–25% of non-certified commercial sports supplements contain undeclared WADA-prohibited substances (such as anabolic-androgenic steroids, SARMs, clenbuterol, sibutramine, or synthetic stimulants like DMAA) due to poor manufacturing cross-contamination or deliberate adulteration. Under the WADA Strict Liability Principle, athletes are personally responsible for any prohibited substance detected in their sample regardless of intent.

8. Adverse Effects & Serious Safety Risks

GHS-R1a/GHRH secretagogues (MK-677, GHRPs, CJC-1295): Severe fluid retention, peripheral oedema, hyperglycaemia/insulin resistance, elevated cortisol and prolactin, carpal tunnel compression, and intense hyperphagia. Unapproved injectable peptides (BPC-157, TB-500): Injection-site cellulitis/abscess, systemic endotoxin fever, immunogenic hypersensitivity/anaphylaxis, and theoretical pro-angiogenic promotion of occult tumour growth.

9. Contraindications & Precautions

ABSOLUTELY CONTRAINDICATED for human self-administration, athletic injury recovery, active or suspected malignancy, diabetes mellitus, pregnancy, and lactation.

10. Drug Interactions

GH secretagogues antagonise insulin and oral antihyperglycaemic medicines; GnRH agonists interact with drugs that prolong the QTc interval.

11. Clinical & Laboratory Monitoring Considerations

Patients who have injected unregulated online peptides require clinical assessment for local/systemic infection, fasting glucose/HbA1c, IGF-1, and pituitary hormone axes.

12. Dependence, Misuse or Withdrawal Concerns

High risk of unmonitored poly-peptide experimentation driven by online misinformation.

13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)

BPC-157, TB-500, Ipamorelin, CJC-1295, GHRP-2/6, and Ibutamoren (MK-677) are UNAPPROVED NEW DRUGS in India under CDSCO and the New Drugs and Clinical Trials (NDCT) Rules, 2019; their sale or compounding for human injection is illegal. Licensed GnRH analogues (Leuprorelin IP) are Schedule H specialist oncology/endocrine prescription drugs.

14. Official WADA Prohibited-List Status

PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S2.2 (Peptide Hormones and Releasing Factors — explicitly listing BPC-157, GnRH analogues, GHRH analogues [CJC-1295, sermorelin, tesamorelin], and GH secretagogues [ghrelin, ibutamoren MK-677, ipamorelin, GHRP-1 to -6, hexarelin]), S2.3 (TB-500 / Thymosin-beta4), and S0 (Non-Approved Substances).

15. Authoritative Source References & Date of Last Verification

Date of Last Verification: 11 November 2026

⚕️ Educational Disclaimer & Medical Supervision Requirement: This monograph is published strictly for academic pharmacy education, anti-doping literacy, and healthcare reference. It does not constitute a medical prescription, sports nutrition endorsement, or athletic dosing advice. Always seek qualified medical supervision before initiating any therapeutic medicine or nutritional intervention.

← Back to All 20 Performance & Endurance Monographs Browse 644 Medicine & Scientific Profiles → 7-Mode Flashcard Study System →